As a Harvard- and UCLA-trained, board-certified medical oncologist, Dr. Kabbinavar brings more than 25 years of academic oncology leadership and over a decade of biopharma drug development experience. He has led oncology programs across academia and industry, advancing therapies from early development through regulatory approval.

At UCLA, Dr. Kabbinavar held dual professorships: 1) Professor of Medicine and 2) Professor of Urologic Oncology and also held the Henry Alvin & Carrie L. Meinhardt Endowed Chair in Cancer Research. He directed multiple oncology programs and served as Chairman of the Institutional Review Board at the Jonsson Comprehensive Cancer Center.

In industry, he has held senior leadership roles including Chief Medical Officer at Cardiff Oncology and Global Head of Research & Development at HUYABIO International, as well as executive positions at Puma Biotechnology and Tocagen, leading clinical strategy and development across oncology programs.

Dr. Kabbinavar has authored more than 100 peer-reviewed publications and has been involved in over 125 clinical trials. His clinical work contributed to the US FDA approval of bevacizumab (Avastin®) in mCRC and atezolizumab (TECENTRIQ®) in ES-SCLC, supporting advancements in oncology treatment.